Abstract:To perform a deep phenotype characterisation in a pedigree of 3 siblings with Leigh syndrome and compound heterozygous NDUFAF6 mutations. Method: A multi-gene panel of childhood-onset basal ganglia neurodegeneration inherited conditions was analysed followed by functional studies in fibroblasts. Results: Three siblings developed gait dystonia in infancy followed by rapid progression to generalised dystonia and psychomotor regression. Brain magnetic resonance showed symmetric and bilateral cytotoxic lesions in … Show more
“…We do not agree with the statement that thiamine is the only compound effective in Leigh-syndrome [1]. In case Leigh syndrome is due to primary coenzyme-Q deficiency, high dose administration of coenzyme-Q can be highly beneficial [2].…”
mentioning
confidence: 80%
“…We read with interest the article by Baide-Mairena et al about three siblings with early-onset Leigh syndrome due to compound heterozygous variants in the NDUFAF6 gene [1]. We have the following comments and concerns.…”
mentioning
confidence: 99%
“…Since the basal ganglia lesions were not only hyperintense on T2/FLAIR sequences but also on diffusion-weighted images (DWI) [1], we should be informed whether apparent diffusion coefficient (ADC) maps showed a corresponding hyperintense or hypointense signal. This is of relevance since ADC hyperintensity would suggest the presence of a stroke-like lesion (SLL), which is the morphological equivalent of a stroke-like episode (SLE).…”
“…We do not agree with the statement that thiamine is the only compound effective in Leigh-syndrome [1]. In case Leigh syndrome is due to primary coenzyme-Q deficiency, high dose administration of coenzyme-Q can be highly beneficial [2].…”
mentioning
confidence: 80%
“…We read with interest the article by Baide-Mairena et al about three siblings with early-onset Leigh syndrome due to compound heterozygous variants in the NDUFAF6 gene [1]. We have the following comments and concerns.…”
mentioning
confidence: 99%
“…Since the basal ganglia lesions were not only hyperintense on T2/FLAIR sequences but also on diffusion-weighted images (DWI) [1], we should be informed whether apparent diffusion coefficient (ADC) maps showed a corresponding hyperintense or hypointense signal. This is of relevance since ADC hyperintensity would suggest the presence of a stroke-like lesion (SLL), which is the morphological equivalent of a stroke-like episode (SLE).…”
“…NDUFAF6 Complex I assembly Dystonia with childhood onset LS Baide-Mairena et al [30] , 2019 SUCLA2 mtDNA depletion Dystonia/ Chorea LS Carrozzo et al [31] , 2007 ATAD3 mtDNA depletion Dystonia Encephalopathy with cerebellar atrophy…”
Section: Surf1mentioning
confidence: 99%
“…Recently, a mutation in NDUFAF6, a complex I assembly factor, has been described in three siblings with childhood onset dystonia associated with bilateral striatal necrosis, neurological regression, and long survival [30] .…”
Mitochondrial disorders (MD) include a large group of maternally inherited, autosomal dominant, or recessive genetic syndromes caused by mitochondrial dysfunction. MD can be diagnosed at any age and many of them show a multisystem presentation with variable combinations of symptoms. Given the important role of mitochondria in neuronal homeostasis, neurological manifestations, including movement disorders, can accompany MD. Movement disorders (MoD), either hypo-or hyperkinetic type, are reported in MD, but the real incidence and a detailed characterization of these features are not addressed in population-based studies. Dystonia, usually in the context of Leigh syndrome, is the main extrapyramidal movement disorder in pediatric MD patients; whereas parkinsonism is the most prevalent hypokinetic disorder in adult MD patients. Ataxia is a common feature in MD, in both the pediatric and adult MD populations. Other MoD, such as myoclonus, chorea, or tremor, may also occur in MD. MoD manifest more frequently in the context of a complex phenotype but rarely can be isolated. From a genetic point of view, MoD are described in patients with either mutations in mtDNA or in nuclear genes related to mitochondria, and the same gene can be associated with different types of MoD. Recent studies demonstrate that the dopaminergic nigrostriatal system is very vulnerable to mitochondrial dysfunction and defects of mtDNA maintenance are frequently associated with a nigrostriatal degeneration, which may explain the pathophysiological mechanism. Therapeutic interventions for MoD in MD do not differ from treatment options used for MoD with different etiopathological background. Some forms benefit from specific treatments, e.g., primary Coenzyme Q10 deficiencies. Newer therapeutic strategies have been pursued which act on different mechanisms of mitochondrial dysfunction, but clinical trials are warranted to improve the management of MD patients.
Mitochondrial disorders are amongst the most frequent inborn errors of metabolism, their primary cause being the dysfunction of the oxidative phosphorylation system (OXPHOS). OXPHOS is composed of the electron transport chain (ETC), formed by four multimeric enzymes and two mobile electron carriers, plus an ATP synthase (also called complex V). The ETC performs the redox reactions involved in cellular respiration while generating the proton motive force used by complex V to synthesize ATP. OXPHOS biogenesis involves multiple steps, starting from the expression of genes encoded in physically separated genomes, namely the mitochondrial and nuclear DNA, to the coordinated assembly of components and cofactors building each individual complex and eventually the supercomplexes. The genetic cause underlying around half of the diagnosed mitochondrial disease cases is currently known. Many of these cases result from pathogenic variants in genes encoding structural subunits or additional factors directly involved in the assembly of the ETC complexes. Here we review the historical and most recent findings concerning the clinical phenotypes and the molecular pathological mechanisms underlying this particular group of disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.